Morgan Stanley
ALGS icon

Morgan Stanley’s Aligos Therapeutics ALGS Stock Holding History

Morgan Stanley’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.18K Sell
204
-14
-6% -$87 ﹤0.01% 7487
2026
Q1 		$1.62K Sell
218
-2,302
-91% -$17.5K ﹤0.01% 7365
2025
Q4 		$23.5K Sell
2,520
-8,764
-78% -$82.7K ﹤0.01% 6644
2025
Q3 		$111K Buy
11,284
+7,279
+182% +$66.5K ﹤0.01% 6109
2025
Q2 		$28.9K Sell
4,005
-3,493
-47% -$20.9K ﹤0.01% 6523
2025
Q1 		$61.9K Buy
7,498
+4,265
+132% +$93.5K ﹤0.01% 6198
2024
Q4 		$129K Buy
3,233
+3,099
+2,313% +$59.9K ﹤0.01% 5960
2024
Q3 		$1.16K Buy
134
+2
+2% +$25 ﹤0.01% 7206
2024
Q2 		$1.16K Hold
132
– – ﹤0.01% 7138
2024
Q1 		$3.23K Buy
132
+52
+65% +$1.03K ﹤0.01% 6987
2023
Q4 		$1.33K Hold
80
– – ﹤0.01% 7101
2023
Q3 		$1.49K Sell
80
-40
-33% -$886 ﹤0.01% 7175
2023
Q2 		$2.91K Sell
120
-5,189
-98% -$139K ﹤0.01% 7114
2023
Q1 		$116K Buy
5,309
+5,215
+5,548% +$199K ﹤0.01% 5951
2022
Q4 		$2.24K Sell
94
-317
-77% -$7.99K ﹤0.01% 7342
2022
Q3 		$11K Sell
411
-1,694
-80% -$56.3K ﹤0.01% 7033
2022
Q2 		$64K Sell
2,105
-1,099
-34% -$37.3K ﹤0.01% 6494
2022
Q1 		$171K Buy
3,204
+1,137
+55% +$91.1K ﹤0.01% 6005
2021
Q4 		$613K Sell
2,067
-16,709
-89% -$6.09M ﹤0.01% 5417
2021
Q3 		$7.28M Buy
18,776
+18,142
+2,862% +$7.18M ﹤0.01% 3288
2021
Q2 		$324K Sell
634
-739
-54% -$471K ﹤0.01% 5763
2021
Q1 		$780K Buy
1,373
+549
+67% +$365K ﹤0.01% 4885
2020
Q4 		$570K Buy
+824
New +$401K ﹤0.01% 4998

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley's ALGS Position: Q2 2026 in Review

Morgan Stanley reduced its Aligos Therapeutics (ALGS) stake by 6.4% in Q2 2026, selling an estimated $87 and leaving 204 shares worth $1.18K. The position accounts for ﹤0.01% of the portfolio, ranked #7487.

Morgan Stanley first reported a position in ALGS in Q4 2020 and has held it in 23 quarters since. The position peaked at $7.28M in Q3 2021. 31 funds tracked by Wall St. Rank hold ALGS as of Q2 2026.

  • Morgan Stanley held 204 shares of Aligos Therapeutics worth $1.18K as of Q2 2026.
  • Morgan Stanley sold 14 Aligos Therapeutics shares in Q2 2026, an estimated $87.
  • Aligos Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7487 holding.
  • Morgan Stanley first reported a position in Aligos Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Morgan Stanley's Aligos Therapeutics position peaked at $7.28M in Q3 2021.
  • 31 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.